MedTrace Logo

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

NCT00479648 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 612

Last updated 2016-07-19

No results posted yet for this study

Summary

Current influenza vaccines have a reduced efficacy in the elderly. This study will investigate the immunogenicity, safety and tolerability of an adjuvanted influenza vaccine in elderly participants.

Conditions

Interventions

BIOLOGICAL

CSL412

BIOLOGICAL

Inactivated trivalent influenza vaccine

Sponsors & Collaborators

  • Seqirus

    lead INDUSTRY

Principal Investigators

  • Elizabeth Hancox, Dr · Chiltern International

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479648 on ClinicalTrials.gov